Archive - The Sarcoma Letter

Neoadjuvant Chemotherapy for High Grade Myxoid Liposarcoma

Some answers, more questions

Feb 19, 2024 •

December 2023

Sarcoma Cellular Therapeutics Initiative

Making Something New

Dec 15, 2023 •

August 2023

Olaparib and Temozolomide

Later Line Treatment of Uterine LMS

Aug 14, 2023 •

July 2023

Trends in FDA Approvals for Sarcoma

Where are we going?

Jul 8, 2023 •

June 2023

Second Opinions

Getting the best information

Jun 18, 2023 •

The Cisplatin Shortage

How does it affect treatment?

Jun 12, 2023 •

How I discuss treatment of desmoid tumors

A patient-centered approach

Jun 9, 2023 •

Reflections on ASCO 2023

The need for more Randomized Controlled Trials

Jun 6, 2023 •

A few ASCO Abstracts

A small selection (there will be more)

Jun 1, 2023 •

May 2023

History and Discovery

May 29, 2023 •

Imatinib Side Effects

Diagnosis and Management of Common Symptoms

May 27, 2023 •

Chemoimmunotherapy for Sarcoma

Doxorubicin and Pembrolizumab

May 23, 2023 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts